Fig. 1: TTK promotes olaparib resistance in OC cells.

A OVCAR8, OV90, and SK/OLA cells were stably transfected with PLKO.NC or TTK shRNA (shTTK1 and shTTK2). TTK protein levels were assessed by Western blot. B OVCAR8, OV90, and UWB1.289 cells were stably transfected with PCMV or PCMV-TTK plasmids. TTK protein levels were determined by Western blot. C, D OVCAR8, OV90, and SK/OLA cells stably transfected with PLKO.NC or TTK shRNA (shTTK1 and shTTK2) were treated with increasing concentrations of olaparib (0, 25, 50, and 100 μM for OVCAR8 and OV90 cells; 0, 25, 50, 100, 200, and 400 μM for SK/OLA cells). The effects of TTK on olaparib sensitivity were measured by MTT assay (C) and colony survival assay (D). Data are mean ± SD, n = 3, one-way ANOVA. a: p relative to TTK knockdown alone; b: p relative to olaparib treatment alone. E, F OVCAR8, OV90, and UWB1.289 cells stably transfected with PCMV or PCMV-TTK plasmids were treated with varying concentrations of olaparib. The effects of TTK on olaparib sensitivity were evaluated by MTT assay (E) and colony survival assay (F). Data are mean ± SD, n = 3, one-way ANOVA. a: p relative to TTK overexpression alone; b: p relative to olaparib treatment alone. (Data are mean ± SD, one-way ANOVA, *P < 0.05, **P < 0.01, n = 3).